EPO (3 Offers)

Composition and form of release

Solution - 1 ml.

Active substance: Erythropoietin beta 2000 IU / 3000 IU or 4000 IU.

Description of the dosage form

The solution is in the form of a colorless transparent liquid.

Pharmacologic effect

Stimulating hematopoiesis.

Pharmacokinetics

After sc administration of Eprex in plasma is achieved after 12-28 hours. T1 / 2 in the final phase is 13-28 hours. After iv administration of T1 / 2 the active substance is 4-12 hours.

Pharmacodynamics

Recombinant human erythropoietin (purified glycoprotein), which is a hematopoietic growth factor. Obtained by genetic engineering. Increases the number of red blood cells, reticulocytes, stimulates the synthesis of hemoglobin in the cells. It does not affect leukopoiesis. It is believed that erythropoietin interacts with specific erythropoietin receptors on the cell surface.

Clinical Pharmacology

The stimulator of erythropoiesis.

Instruction manual

Inject it subcutaneously and intravenously.

Indications

• Severe anemia that occurs against the background of chronic renal failure;
• Anemia in bone marrow lesions and some chronic diseases (including aplastic anemia, anemia in myelodysplastic diseases, chronic inflammatory diseases, AIDS, cancer);
• Anemia in preterm infants born with a body weight of 750-1500 g before the 34th week of pregnancy;
• An increase in the volume of donated blood intended for subsequent autotransfusion in order to avoid blood transfusion;

Contraindications

Uncontrolled hypertension, myocardial infarction or cerebral stroke during the previous month, unstable angina pectoris, history of thromboembolism, hypersensitivity to epoetin beta.

Used with caution in case of epilepsy, thrombocytosis, liver failure, vascular insufficiency, and malignant neoplasms; in patients with nephrosclerosis who are not receiving hemodialysis, since a more rapid deterioration of renal function is possible.

Use during pregnancy and children

During pregnancy, only if the intended benefit to the mother significantly exceeds the potential risk to the fetus.

Side Effects

From the cardiovascular system: arterial hypertension, hypertensive crisis are possible.

From the side of the central nervous system: encephalopathy is possible (more often with hypertensive crises), headache, confusion.

From the blood coagulation system: rarely - thrombocytosis, thrombotic complications.

From the side of metabolism: rarely - hyperkalemia.

Allergic reactions: rarely - skin rash, anaphylactoid reactions.

Drug interaction

With the simultaneous use of drugs that affect blood formation (for example, iron preparations), the stimulating effect of epoetin beta may increase.

Dosage

Initial doses are 50-150 IU / kg, the frequency of administration is on average 3 times a week.